TRPM8 channel blockers as a potential new pharmacological class for the treatment of migraine
Expert Review of Clinical Pharmacology · 17.11.2026
DOI: 10.1080/17512433.2026.2767108 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 17.11.2026. Verfasst von Lanfranco Pellesi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Die Arbeit nennt 87 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Migraine therapy has advanced in recent years, particularly with the emergence of calcitonin gene-related peptide (CGRP)-targeting drugs. However, acute treatment still faces limitations, especially in patients who are unresponsive to or unable to take triptans or gepants. Transient receptor potential melastatin 8 (TRPM8) is a polymodal-gated, nonselective cation channel that represents a promising target for the treatment of migraine supported by genetic, preclinical and clinical evidence. AREAS COVERED: This review covers the evidence supporting an important role for TRPM8 in the pathophysiology of migraine and provides a detailed synopsis of the preclinical, pharmacodynamic and pharmacokinetic profiles of potential TRPM8-interacting compounds in clinical development for the treatment of migraine. PubMed and ClinicalTrials.gov were searched to August 2026 for TRPM8 and migraine, supplemented by 2026 congress abstracts and company disclosures. EXPERT OPINION: TRPM8 channel blockade has a mechanistically distinct approach from current therapeutics. A proof-of-concept and dose range finding Phase 2 study with elismetrep, a novel, oral TRPM8 blocker, provides supportive, although not definitive, evidence for TRPM8 blockers in migraine. Although the primary endpoint of 2-hour pain freedom was not statistically significant, numerically greater effects at 20 mg and nominally significant secondary-endpoint findings support further development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy.
- TriGemX Bio, Inc., New York, NY, USA.
- Internal Medicine, Faculty of Medicine and Dentistry, Sapienza University, Rome, Italy.
- School of Health, Unitelma Sapienza University of Rome, Rome, Italy.
Zitieren
APA
Pellesi, L., Chiarugi, A., Kupferman, J., Crutchlow, M., & Martelletti, P. (2026). TRPM8 channel blockers as a potential new pharmacological class for the treatment of migraine. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2767108
Vancouver
Pellesi L, Chiarugi A, Kupferman J, Crutchlow M, Martelletti P. TRPM8 channel blockers as a potential new pharmacological class for the treatment of migraine. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2767108
BibTeX
@article{Pellesi2026,
author = {Pellesi, Lanfranco and Chiarugi, Alberto and Kupferman, Justine and Crutchlow, Michael and Martelletti, Paolo},
title = {TRPM8 channel blockers as a potential new pharmacological class for the treatment of migraine},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
doi = {10.1080/17512433.2026.2767108}
}
EUVIMED